Intravesical Treatment
Intravesical Treatment - Related Videos
08:43
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
0 Views •
Cited by 12 •
2012
Establishing an orthotopic bladder tumor model to evaluate antitumor effects of intravesically delivered saRNA and monitoring tumor growth by ultrasound and bioluminescent imaging.
04:28
Modeling Orthotopic Bladder Tumor in Mouse Model: A Procedure for Intravesical Administration of Cancer Cells into Murine Bladder
0 Views •
2023
In this video, we describe the intravesical procedure of delivering cancer cells into the bladder of a mouse model. This procedure helps generate an orthotopic bladder tumor model that can be used to develop therapeutic strategies.
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
0 Views •
Cited by 26 •
2013
Psoriasis is a chronic, immune-mediated inflammatory skin disease. The Goeckerman regimen, formulated for the treatment of psoriasis, consists of exposure to ultraviolet B (UVB) light and application of crude coal tar (CCT). The following protocol is for the administration of Goeckerman therapy for the treatment of moderate-to-severe psoriasis.
08:20
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
0 Views •
Cited by 31 •
2015
Here we outline the procedure for MRI-guided repetitive transcranial magnetic stimulation to the dorsomedial prefrontal cortex as an experimental treatment for major depressive disorder.
08:01
Rockwell Hardness Test and the Effect of Treatment on Steel
0 Views •
2023
Source: Roberto Leon, Department of Civil and Environmental Engineering, Virginia Tech, Blacksburg, VA Hardness testing is one of the most universally valuable mechanical tests available to engineers, as it is both simple and relatively inexpensive for the wealth of information and data it produces. Hardness testing, generally in the form of a surface penetration test, is both quicker and less destructive than tensile testing. Hardness provides a linear relationship with tensile strength over a...
FAQs
The therapeutic rationale rests on concentrating medication where disease is located: the bladder and lower urinary tract. Direct contact may increase exposure of bladder tissue compared with relying entirely on medication distributed through the body. At the same time, this approach can reduce dependence on systemic distribution, making localized delivery an important consideration in urologic care.
Dwell time determines how long the medication remains in contact with bladder tissue before drainage. Because intravesical treatment uses a defined retention period, clinicians can structure delivery around controlled local exposure rather than immediate removal. The timing therefore becomes a key procedural condition that may influence how effectively the bladder receives the intended therapy.
Unlike a route that depends primarily on systemic distribution, this approach places medication in the bladder before it is drained. Its distinguishing feature is the intended local contact with lower-urinary-tract tissue, while systemic distribution is not the sole delivery pathway. This distinction helps explain its role in targeted urologic therapy.
A clinician typically introduces the medication into the bladder through a catheter, allows it to remain there for a specified dwell time, and then drains the bladder. These steps create a controlled sequence of administration, local exposure, and removal. The procedure is therefore organized around both catheter delivery and timed contact with bladder tissue.
In urologic care, intravesical treatment may be used for bladder cancer as well as inflammatory or irritative bladder disorders. These applications reflect the value of directing therapy toward the lower urinary tract rather than treating every condition through broad systemic distribution. The specific clinical use depends on the bladder disorder being managed.
The method supports research into localized therapies that may improve how effectively medication contacts bladder tissue while reducing reliance on systemic distribution. Investigators can therefore study treatments designed specifically for the lower urinary tract, including approaches relevant to bladder cancer and inflammatory or irritative disorders. This research also considers whether localized delivery can be better tolerated.